MQIX's rapid and accurate diagnosis enables anyone to easily and accurately perform correct treatment and prevention.

HAUUL Bio believes that our research can become a means of invigorating and enriching life and changing the world by developing what humanity needs.


By creating an in vitro diagnostic medical device platform in 2022, we have laid the foundation for commercializing rapid in vitro diagnostic kits for diagnosing infectious diseases.

From 2023, we will expand our in vitro rapid diagnostic kit pipeline for infectious disease diagnosis. This will allow us to continuously expand the global market through mutual trust with Korean and international partners and contribute to developing infectious disease diagnostic systems.

In the future, we will implement a smart healthcare system that enables the prediction and prevention of infectious diseases, diagnosis, customized treatment, and prognosis after treatment.


Hauul Bio will contribute to the balance of the health and happiness of humankind through rapid and accurate diagnosis of infectious diseases and illnesses.